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BACKGROUND: The aim of the study was to assess the role of 
planar lymphoscintigraphy and fusion imaging of SPECT/CT in sen-
tinel lymph node (SLN) identification in patients with melanomas.
MATERIAL AND METHODS: Planar and hybrid SPECT/low-dose 
CT lymphoscintigraphy were performed in 113 consecutive pa-
tients with melanomas (59 men, 54 women, mean age 57.6 with 
range 11–87 years, BMI 29.4 ± 12.5). The radiopharmaceuti-
cal was injected around the tumour (Group A, 59 patients), or 
around the scar (Group B, 54 patients). Localisation of mela-
nomas: head and neck 4, trunk 55, upper extremities 28, lower 
extremities 26. Planar and SPECT/CT images were interpreted 
separately by two nuclear medicine physicians. Abilities of these 
two techniques to image SLN were compared.
RESULTS: SLNs were detected on lymphoscintigraphy compris-
ing planar and SPECT-CT images in 108 (95.6%) study patients; 
there was failure to detect SLNs in the remaining 5 (4.4%) pa-
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tients. Planar images identified 253 SLNs in 100 (88.5%) pts, 
with a mean of 2.2 ± 1.7 (range 0–9 nodes) per patient. In the 
remaining 13 (11.5%) patients no SLNs were detected on planar 
images. On SPECT-CT images, 334 hot nodes were detected 
in 107 (94.7%) patients with a mean of 3.0 ± 2.1 (range 0–9) 
nodes per patient. In the remaining 6 (5.3%) patients, SPECT-CT 
was negative.
SPECT/CT visualised lymphatic drainage in 8 (7.1%) patients 
with non-visualisation on planar imaging.
CONCLUSIONS: In some patients with melanomas SPECT/CT 
improves detection of sentinel lymph nodes. It can image nodes 
not visible on planar scintigrams, exclude false positive uptake 
and exactly localize SLNs. 
KEY words: sentinel node, malignant melanoma, 
lymphoscintigraphy, planar scintigraphy, SPECT/CT
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Background
In patients with a histopathologic diagnosis of cutaneous mela-
noma, the tumour must be staged to determine prognosis and 
treatment. Tumour thickness is the single most important prognos-
tic factor. Melanoma is staged with the TNM system. Preoperative 
lymphoscintigraphy can contribute to nodal staging by revealing 
lymphatic drainage patterns and the locations of single or multiple 
sentinel lymph nodes [1]. It helps the surgeon to minimise the 
size of the incision. 
SLN biopsy is the most accurate and the only reliable method 
for nodal staging which can diagnose microscopic tumour spread 
to the regional lymph nodes. Lymphoscintigraphy visualises where 
lymph from the primary tumour site travels and is, therefore, an es-
sential element of lymphatic mapping [2, 3]. 
An essential step in the procedure for SLN biopsy is to lo-
cate the first-echelon node of draining basin. In some patients, 
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however, the lymphoscintigram shows a drainage pattern that 
is difficult to interpret and in a small minority no sentinel node 
is depicted at all [4].
In this study we compare hybrid SPECT/CT and planar lym-
phoscintigraphy in melanoma patients with exploration the value 
of SPECT/CT — mainly for detection of additional SLNs and the 
exact anatomical localization of SLNs. 
Materials and methods
Patients population: Planar and hybrid SPECT/low-dose 
CT lymphoscintigraphy were performed in 113 consecutive 
patients (59 men, 54 women, mean age 57.6 with range 11–87 
years, BMI 29.4 ± 12.5) with malignant melanoma, with no clinical 
evidence of lymph node metastases (N0) and no remote metasta-
ses (M0). 55 patients had melanoma on their trunk, 4 in the head 
and neck region, and 54 on an extremity (upper extremity 28, lower 
extremity 26). In all these 113 patients, SPECT/CT images were 
made immediately after the conventional images without a second 
injection of the radiopharmaceutical.
Lymphoscintigraphic method: On the day of surgery (one day 
protocol) an activity of 100 MBq 99mTc labelled colloid divided in 
four equal aliquots of 0.5 ml was injected by nuclear medicine 
physician in four intradermal injection around the tumour (59 pts, 
Group A) or around the scar (54 pts, Group B) after excision of the 
melanoma. We have used following 99mTc colloids: Nanocis (size 
of colloid particles 100 nm — 12 pts), Nanocoll (size of colloid 
particles to 80 nm — 75 pts), SentiScint (size of particles to 200 
nm — 1 pt), NanoAlbumon (size of particles to 80 nm — 25 pts). 
Choice of radiopharmaceuticals (Rf) was totally random. Type of Rf 
was not important because we have compared planar scintigraphy 
and SPECT/CT performed by the same Rf. We estimated effective-
ness of various Rf for the detection of SLNs in our previous pa-
pers [5–8] and that was not the aim of this study. Furthermore we 
did not compare the rate of successful preoperative and perop-
erative detections of SLNs, which was also described previously. 
Planar static (parameters: matrix 128 × 128, 5 min per view) 
and dynamic scintigraphy (parameters: matrix 128 × 128, 30 
frames, 20 s per frame) and SPECT/CT lymphoscintigraphy were 
performed using a hybrid system composed of a dual-head 
gamma camera with a low-dose CT installed in a gantry (Symbia 
T2 Siemens).
SPECT/CT images were acquired immediately after planar 
images. The SPECT/CT system (Symbia T2; Siemens, Erlangen, 
Germany) consisted of a dual-head variable-angle gamma cam-
era equipped with low-energy high-resolution collimators and 
a two-slice spiral CT scanner optimized for rapid rotation. SPECT 
acquisition (matrix 128 × 128, 60 frames at 20 s per view) was per-
formed using steps of 6°. For CT (130 kV, 17 mA, B60s kernel), 
5 mm slices were created. The iterative reconstruction (OSEM 3D) 
was used for generating SPECT slices.
Both SPECT and CT slices were fused using an Esoft 2000 
application package software (Siemens, Erlangen, Germany). Two 
nuclear medicine physicians evaluated the images. The SPECT/CT 
images were also viewed using two-dimensional orthogonal 
re-slicing in axial, sagittal and coronal orientation. Maximum 
intensity projections with a three-dimensional display were gener-
ated to localize sentinel nodes in relation to anatomic structures. 
Image analysis was performed prospectively by two expe-
rienced nuclear medicine physicians in consensus reading. All 
images were analysed in two steps: 1. analysis of planar images; 
2. analysis of coregistered SPECT/CT images. The location of 
SLNs was categorised as axillar, inguinal and in other lymphatic 
basins. 
In the analysis of the results, fused SPECT/CT images data 
were concluded to be clinically relevant if they identified SLNs which 
were missed on planar images, if they excluded SLN suspected 
on planar images, or if they localized SLNs in additional or diffe-
rent basins than those suggested by planar images. The surgeon 
is notified of the findings on both planar and SPECT/CT images. 
Student’s paired t-test was used for comparing numbers of found 
nodes by both techniques. Values were considered significant 
when P < 0.05.
Results
SLNs were detected on lymphoscintigraphy comprising pla-
nar and SPECT-CT images in 108 (95.6%) study patients; there 
was failure to detect SLNs in the remaining 5 (4.4%) patients. 
SPECT/CT visualized lymphatic drainage in 9 (8,0%) pa-
tients with non-visualization on planar imaging. SPECT/CT showed 
the exact anatomical location of all visualized sentinel nodes.
Planar images identified 253 SLNs in 100 (88.5%) pts, with 
a mean of 2.5 ±1.6 (range 0–9 nodes) per patient. In the remaining 
13 (11.5%) patients no SLNs were detected on planar images. On 
SPECT-CT images, 334 hot nodes were detected in 107 (94.7%) 
patients with a mean of 3.1 ± 2.1 (range 0–9) nodes per patient. In 
the remaining 6 (5.3%) patients, SPECT-CT was negative. Among 
the patients in whom SPECT-CT identified hot nodes, the location 
of these nodes was as follows (Table 1).
The overall hot SLN detection rate by planar and SPECT-CT 
lymphoscintigraphy in GROUP A was 98.3% (58 patients). In 1 
patient (1.7%) both imaging techniques failed to detect hot SLNs. 
In 4 patients (6.8%), hot SLNs were detected only by SPECT-CT 
and there was no patient with a hot SLN detected only by planar 
images. 
Table 1. Location of SLNs
 GROUP A GROUP B OVERALL
 SPECT/CT Planar SPECT/CT Planar SPECT/CT Planar
Axilla 98 57 83 48 181 105
Inguina 49 22 50 37 99 59
Others 25 9 29 11 54 20
Equivocal 0 46 0 23 0 69
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The overall hot SLN detection rate on planar and SPECT-CT in 
GROUP B was 92.6% (50 patients). In 4 patients (7.4%) both planar 
and SPECT-CT imaging failed to detect hot SLNs and in 5 (9.3%) 
patients, hot SLNs were detected only on SPECT/CT images.
Discordant results between planar and SPECT-CT nodal iden-
tification (Figure 1, 2): SPECT-CT was positive in 9 patients with 
negative planar imaging, while conversely, positive planar imaging 
and negative SPECT-CT were found only in 1 patient. 
SPECT/CT showed higher number of hot lymph nodes in 49 
patients (43,4%, range 1–6 nodes), in the GROUP A it was in 
23 patients (39,0%, range 1–5 nodes), and in the GROUP B it 
was in 26 patients (48,1%, range 1–6 nodes). The number of 
SLNs was exactly the same in 58 patients (51,3%), in the GROUP 
A in 33 (55,9%) patients, in the GROUP B in 25 (46,3%) patients.
In 26 patients (23,0%), the exact anatomical localization 
was equivocal on planar images, whereas SPECT/CT showed 
the exact anatomical information. In one patient in GROUP 
A SPECT/CT revealed superficial contamination.
In general, the SPECT/CT imaging brought statistically higher 
numbers of found hot lymph nodes, compared to planar scintigra-
phy, in both groups (P < 0.001 for both groups). Comparing both 
groups together, there are about 20% more cases in GROUP B, 
where hybrid scans visualized higher number of nodes than in 
GROUP A. Respectively, the situation, where sentinel lymph node 
was detected only on hybrid images, there was approximately 40% 
higher in GROUP B than in GROUP A.
Discussion
A sentinel node was defined as a lymph node upon which the 
primary tumour drains directly [9], i.e. the first lymph node that 
is at risk from metastatic cells [10]. 
The histopathologic findings in the excised SLNs may indicate 
the need for a further dissection of the nodal basin if metastatic 
spread or micrometastases are found. Alternatively, if the SLN 
is tumour free, the nodal basin can be regarded as free of di-
sease and an unnecessary dissection can be avoided. Even in 
the era of emerging tumour imaging modalities, such as PET/CT, 
SLN biopsy is considered the only reliable method for identifying 
micrometastatic disease in regional lymphatic nodes [11]. SLN 
biopsy is considered the „gold standard“ investigation tool for the 
detection of lymph node metastases [12]. 
In patients with cutaneous melanoma, in particular, the SLN 
status has been found to be strongly prognostic [13]. Because 
elective lymph node dissection has not been shown to improve 
the survival benefit in patients with melanoma [14], the accurate 
localization of SLN for tissue sampling has become increasingly 
important for clinical management. The survival of melanoma pa-
tients staged as node-negative with elective regional lymph node 
dissection was significantly less as compared to patients staged 
as node-negative following sentinel lymph node biopsy, regard-
less of their T stage [15]. Melanoma patients are staged more 
accurately following SLN assessment [16]. 
SLN biopsy in patients with clinically node-negative malignant 
melanoma is a valuable procedure for nodal staging and for 
prognostic stratification [17]. It allows the detection of clinically 
occult metastases by an exhaustive histopathological examination. 
Accurate visualization of the SLN is required for the best results. 
The variability of SLN drainage in melanoma in areas such as the 
trunk, the head and the neck makes lymphoscintigraphy very 
useful [18]. Lymphoscintigraphy has been found to accurately 
predict the number of nodes in only 81% of the basins, overlooking 
nodes that were superimposed and could not be separated from 
other nodes or from the injection site or lymphatic channels and 
nodes that were beyond the resolution of the planar images [19]. 
The better anatomic definition and improved resolution that 
characterise SPECT images may overcome the above limitations of 
planar images. Localization of hot lymph nodes on SPECT ima-
ges without anatomic landmarks is not possible.
SPECT/CT was introduced in lymphatic mapping with the goal 
to show more sentinel nodes and to show them more clearly than 
is possible with conventional lymphoscintigraphy. 
Hybrid SPECT/CT camera fuses tomographic lymphoscinti-
grams (physiological information) with anatomical data from CT 
[20, 21]. In comparison with traditional single-modality imaging 
approaches, the dual-modality systems offer unique capabilities in 
combining data from two imaging modalities in way that simpli-
fies, yet facilitates, image correlation with the goal of revealing 
useful diagnostic information that is not easily extracted when 
the imaging studies are performed independently [22]. Hybrid 
SPECT/CT provides better contrast and resolution than planar 
imaging with possibility to correct an attenuation and scatter [23, 
24]. SPECT/CT images provide the topographic landmarks that 
may further facilitate surgical exploration [21] with improvement 
Figure 1. Numbers of found lymph nodes on SPECT/CT and planar 
imaging in GROUP A
Figure 2. Numbers of found lymph nodes on SPECT/CT and planar 
imaging in GROUP B
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of surgical SLNs detection. If only used to correct the radionuclide 
image for photon attenuation, the CT data can be acquired with 
a considerably lower statistical quality and coarser spatial resolu-
tion than required for diagnostic-quality imaging and therefore can 
deliver a significantly lower radiation dose than that for a diagnostic 
CT study [22]. Hybrid system allows transmission (low-dose CT) 
and emission (SPECT) scans to be performed without changing 
the patient’s position, thereby allowing for automatic and correct 
record of images obtained with two modalities. Fusion of two im-
ages into one image is easier [21, 25].
The introduction of hybrid SPECT/CT into daily practice 
is associated with additional costs and requires extra time [4]. 
The advantages of additional SPECT/CT may prevail when used 
in specific situation only [26]. In special instances, SPECT/CT 
imaging allows for improved detectability and interpretation of 
lymphatic drainage. Contamination, nodes close to the injection 
site, and overweight patients are three noted instances in which 
SLN identification and localization are better with SPECT than 
with standard planar methods [27, 28]. In malignant melanoma 
dynamic lymphoscintigraphy and fusion of SPECT and CT can 
detect aberrant pelvic SLNs [10]. 
Besides melanoma [17], the use of SPECT/CT has been 
described in SLN lymphadenectomy for breast cancer, head and 
neck cancer, prostate cancer, bladder cancer, vulvar, cervical and 
endometrial cancer - the value of SPECT/CT for SLN identification 
and localization has been described in several reports [12, 29–37]. 
Low radiation dose is added to the scintigraphic mapping by 
the low-dose CT, ranging from 1.3 mGy at the centre to 5 mGy at 
the surface of the body [21, 38]. 
SPECT/CT should be performed in selected patients, i.e. those 
with an unusual lymphatic drainage pattern, with planar images that 
are difficult to interpret or with no visualization on planar images. 
In these patients, SPECT/CT appears to have additional value. 
The use of SPECT as well as coregistered CT images in vaginal 
melanoma proves to be useful in detection and localization of 
SLN not seen on planar imaging alone for use in staging and 
treatment planning [39].
SPECT/CT provides an anatomical overview in two- and 
three-dimensional perspectives creating a surgical road-map that 
cannot be provided by planar images or intraoperative lymphatic 
mapping techniques. The present study confirms the additional 
value of SPECT/CT in the anatomical localization of (additional) 
SLNs. Other investigators have also concluded that additional 
SPECT/CT after planar lymphoscintigraphy resulted in an improved 
anatomical localization of SLNs. Especially SLNs outside the axilla 
and nodes close to the injection site were easier to identify using 
SPECT/CT [26]. SPECT/CT was able to accurately bring to light 
sites of skin contamination with the radiopharmaceutical, that were 
mistaken for sentinel nodes in 1 patient (0.88%) on planar images. 
The problem is masking of the sentinel node by the injected 
tracer because of the close proximity of the tumour site to the 
draining node. Most often, the sentinel node is overlooked because 
of the smear of the tracer overlying the draining node [40], i.e. the 
“shine effect“[41]. 
Van der Ploeg et al. [26] limited the use of SPECT/CT to 
difficult and unusual cases because they believe planar lym-
phoscintigraphy is an excellent preoperative mapping technique 
for most patients. They added nonvisualization as a new indica-
tion, because SPECT/CT visualized drainage in patients whose 
planar images did not reveal a SLN. They believe that the added 
costs and extra time for SPECT/CT are more justified when the 
procedure is used for this new indication. SPECT/CT is useful 
for finding the exact anatomic location of sentinel nodes and 
in detecting additional sites of drainage. The use of routine 
SPECT/CT imaging is very suitable in vaginal melanoma for pelvic 
lymphoscintigraphic studies or as an adjunct tool for localizing 
SLN in cases that would not be demonstrated with planar imaging 
alone [39]. Preoperative SPECT/CT lymphoscintigraphy is ideal for 
mapping the unpredicted lymphatic drainage pathways within the 
complex pelvic anatomy in vulvovaginal melanoma [42]. These ad-
vantages facilitate surgical exploration and eventually lead to more 
accurate staging. SPECT/CT may also obviate preoperative skin 
marking and may replace delayed lateral planar imaging. Whether 
SPECT/CT should be used on all patients or only for specific indica-
tions needs to be studied further [26]. The better anatomic defini-
tion and improved resolution that characterise SPECT images may 
overcome limitations of planar images. Localisation of hot lymph 
nodes on SPECT images without anatomic landmarks is not 
possible. However, it is possible by fusing the SPECT image with 
the anatomic data obtained by performing low-dose CT at the 
same setting as with the SPECT acquisition [20]. Van Ploeg et al. 
in other paper [43] concluded that SPECT/CT detects additional 
drainage and shows the exact anatomical location of sentinel 
nodes in patients with inconclusive conventional lymphoscin-
tigrams. SPECT/CT justifies the additional time and costs for 
patients in whom conventional lymphoscintigrams shows a lym-
phatic drainage pattern that is unusual or difficult to interpret, or 
when no sentinel node is shown. SPECT/CT better visualizes the 
sentinel nodes in more than half of the patients and changes the 
surgical approach in more than a third. In a fair number of patients, 
additional sentinel nodes are detected that would have not been 
found otherwise. SPECT/CT facilitates surgical exploration in dif-
ficult cases and may improve staging.
Even-Sapir et al. [20] concluded that the improved lesion de-
tectability of tomographic images and the anatomic landmarks of 
CT would be the more likely explanation for the additional data 
provided by SPECT/CT but potential explanations for identifica-
tion of additional nodes by SPECT/CT could have been the effect 
of time, inadequate planar technique, or improved tomographic 
imaging technology. 3-D SPECT/CT images may identify hidden 
nodes due to a good separation between counts related to the 
tracer injection and those of a closely located hot lymph node 
[25] (Figure 3, 4). 
Conclusions
SPECT/CT shows the exact anatomical location of visualized 
sentinel nodes and detects additional drainage, compared with 
planar scintigraphy — in our study this was observed in 43.3% 
of patients examined. Furthermore, hybrid imaging brought ad-
ditional value especially in the group of patients with scar after 
extirpation of melanoma, where SPECT/CT visualized higher 
number of SLNs in 20% more cases than in the group of pa-
tients prior the primary surgery. This should be also taken into 
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Figure 3. Dynamic and static lymphoscintigrams in 59 years old man with melanoma on the left side of the back with no possibility the exact locali-
zation of the SLNs
Figure 4. The same patient as in the figure 3. Fusion of SPECT and CT. Exact localization of two SLNs in the left axilla, and two SLNs in the right 
axilla
account, if there is need to narrow the patient selection for the 
examination on hybrid camera. The added radiation exposure 
from CT source should be considered. According to low-dose 
scanning protocol we evaluated the radiation exposure from 
spiral CT to about 1.5 millisieverts (mSv). The hybrid system al-
lows the CT scanning following SPECT acquisition directly. There 
is not needed additional manipulation with patient, so the total 
acquisition time is not prolonged considerably. 
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